semaglutide and leptin as a Potential Modifier of Neuroinflammation: Contrasting Roles in Alzheimer's Disease Multiple Sclerosis A cellular and molecular basis

It means we do not yet have structured evidence defining expected fat loss, lean mass changes, long-term durability, or safety at those lower doses

3 Neither medication has shown significant safety concerns in clinical trials when prescribed and monitored appropriately

WEGOVY is not recommended in patients with severe gastroparesis. The label does not mention that Wegovy could cause gastroparesis, a claim in many Wegovy lawsuits

In addition, the role of emerging dual incretin therapies in cardiometabolic care requires further investigation, particularly regarding their cardiovascular and kidney benefits and their use alongside SGLT2is

These potential side effects are typically mild and are usually dose dependent